Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ambrx Biopharma, Inc. - Common Stock (NY:AMAM)

N/A UNCHANGED
Last Price Updated: 7:00 PM EDT, Mar 16, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ambrx Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday! 
Via InvestorPlace
NetScout Systems, Ericsson And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Cancer Focused Ambrx Biopharma Stock Trading Lower Today - Here's Why
Ambrx Biopharma Inc (NASDAQ: AMAM) announced that two abstracts detailing updated safety and efficacy data from the ongoing Phase 1/2 trial, APEX-01, evaluating ARX517 for metastatic... 
Via Benzinga
Why Shares of Ambrx Biopharma Soared This Week
A big buy by an asset manager spurred interest in the biotech stock. 
Via The Motley Fool
Where Ambrx Biopharma Stands With Analysts
Via Benzinga
Expert Ratings for Ambrx Biopharma
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Ambrx Biopharma
Via Benzinga
Why Shares of Ambrx Biopharma Jumped This Week
The company reported data on its clinical programs at two conferences this week. 
Via The Motley Fool
Ambrx Biopharma Highlights Preclinical Data From Studies in Kidney, Prostate Cancer
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why ContraFect Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Gainers LQR House Inc. (NASDAQ: LQR) shares surged 109% to $0.3602 in pre-market trading after the company delivered inaugural order to Costco, securing Von Payne Whiskey's presence on store shelves. 
Via Benzinga
Domino's, Walgreens, Fastenal And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mixed, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Via Benzinga
Around $19M Bet On Westrock Coffee? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
PTC Therapeutics, Planet Fitness, Kemper And Other Big Stocks Moving Lower On Friday
U.S. stocks traded higher, with the Dow Jones falling around 180 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
Via Benzinga
Ambrx Biopharma Has Surged 483% This Year. But It Could Just Be Getting Started.
The company has another update on its prostate cancer program that could further prod shares. 
Via Investor's Business Daily
Unique ADC Constructs Boost Ambrx Biopharma's Profile: Analyst Sees Optimistic Outlook
RBC Capital Markets initiated coverage on Ambrx Biopharma Inc (NASDAQ: AMAM) With an Outperform rating and a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating
B Riley Securities has initiated Ambrx Biopharma Inc (NASDAQ: AMAM) with a Buy rating and a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
Via Benzinga
Ambrx Biopharma's Oncology Pipeline Is Underappreciated, Analyst Initiating Coverage Says
Cantor Fitzgerald initiated coverage on Ambrx Biopharma Inc (NASDAQ: AMAM) with an Overweight rating and a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 19, 2023
Via Benzinga
Why Sunrise New Energy Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
$59M Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed lower on Thursday, there were a few notable insider trades. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.